{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:02:12Z","timestamp":1794085332902,"version":"4.8.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,12,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The persistence of minimal residual disease (MRD) during therapy is the strongest adverse prognostic factor in acute lymphoblastic leukemia (ALL). We developed a high-throughput sequencing method that universally amplifies antigen-receptor gene segments and identifies all clonal gene rearrangements (ie, leukemia-specific sequences) at diagnosis, allowing monitoring of disease progression and clonal evolution during therapy. In the present study, the assay specifically detected 1 leukemic cell among greater than 1 million leukocytes in spike-in experiments. We compared this method with the gold-standard MRD assays multiparameter flow cytometry and allele-specific oligonucleotide polymerase chain reaction (ASO-PCR) using diagnostic and follow-up samples from 106 patients with ALL. Sequencing detected MRD in all 28 samples shown to be positive by flow cytometry and in 35 of the 36 shown to be positive by ASO-PCR and revealed MRD in 10 and 3 additional samples that were negative by flow cytometry and ASO-PCR, respectively. We conclude that this new method allows monitoring of treatment response in ALL and other lymphoid malignancies with great sensitivity and precision. The www.clinicaltrials.gov identifier number for the Total XV study is NCT00137111.<\/jats:p>","DOI":"10.1182\/blood-2012-07-444042","type":"journal-article","created":{"date-parts":[[2012,10,18]],"date-time":"2012-10-18T09:49:24Z","timestamp":1350553764000},"page":"5173-5180","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":371,"title":["Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"120","author":[{"given":"Malek","family":"Faham","sequence":"first","affiliation":[{"name":"Sequenta Inc, South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbiao","family":"Zheng","sequence":"additional","affiliation":[{"name":"Sequenta Inc, South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Moorhead","sequence":"additional","affiliation":[{"name":"Sequenta Inc, South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria E. H.","family":"Carlton","sequence":"additional","affiliation":[{"name":"Sequenta Inc, South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Stow","sequence":"additional","affiliation":[{"name":"Department of Oncology, St Jude Children's Research Hospital, Memphis, TN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Coustan-Smith","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hon","family":"Pui","sequence":"additional","affiliation":[{"name":"Department of Oncology, St Jude Children's Research Hospital, Memphis, TN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Campana","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111809113433600_B1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1053\/j.seminhematol.2008.09.003","article-title":"Treatment of adult acute lymphoblastic leukemia.","volume":"46","author":"G\u00f6kbuget","year":"2009","journal-title":"Semin Hematol"},{"issue":"5","key":"2019111809113433600_B2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","article-title":"Biology, risk stratification, and therapy of pediatric acute leukemias: an update.","volume":"29","author":"Pui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111809113433600_B3","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/leu.2009.268","article-title":"Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.","volume":"24","author":"Br\u00fcggemann","year":"2010","journal-title":"Leukemia"},{"key":"2019111809113433600_B4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/asheducation-2010.1.7","article-title":"Minimal residual disease in acute lymphoblastic leukemia.","volume":"2010","author":"Campana","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"2019111809113433600_B5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"issue":"23","key":"2019111809113433600_B6","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1182\/blood-2009-11-253435","article-title":"Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.","volume":"115","author":"Stow","year":"2010","journal-title":"Blood"},{"issue":"26","key":"2019111809113433600_B7","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation.","volume":"360","author":"Pui","year":"2009","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111809113433600_B8","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1182\/blood-2010-12-324004","article-title":"New markers for minimal residual disease detection in acute lymphoblastic leukemia.","volume":"117","author":"Coustan-Smith","year":"2011","journal-title":"Blood"},{"key":"2019111809113433600_B9","article-title":"Monitoring health and disease status using clonotype profiles.","author":"Faham","year":"2011","journal-title":"US patent application 2011\/0207134A1"},{"issue":"7381","key":"2019111809113433600_B10","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer.","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"issue":"3","key":"2019111809113433600_B11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0609.1999.tb01765.x","article-title":"Clonal evolution as judged by immunoglobulin heavy chain gene rearrangements in relapsing precursor-B acute lymphoblastic leukemia.","volume":"63","author":"Rosenquist","year":"1999","journal-title":"Eur J Haematol"},{"issue":"3","key":"2019111809113433600_B12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood.V81.3.775.775","article-title":"Immunoglobulin heavy chain gene VH-D junctional diversity at diagnosis in patients with acute lymphoblastic leukemia.","volume":"81","author":"Kitchingman","year":"1993","journal-title":"Blood"},{"issue":"2","key":"2019111809113433600_B13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1182\/blood.V82.2.581.581","article-title":"Distinct ongoing Ig heavy chain rearrangement processes in childhood B-precursor acute lymphoblastic leukemia.","volume":"82","author":"Steenbergen","year":"1993","journal-title":"Blood"},{"issue":"6","key":"2019111809113433600_B14","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1182\/blood.V87.6.2506.bloodjournal8762506","article-title":"Clonal evolution in B-lineage acute lymphoblastic leukemia by contemporaneous VH-VH gene replacements and VH-DJH gene rearrangements.","volume":"87","author":"Choi","year":"1996","journal-title":"Blood"},{"key":"2019111809113433600_B15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.0105-2896.2004.0107.x","article-title":"The molecular basis and biological significance of VH replacement.","volume":"197","author":"Zhang","year":"2004","journal-title":"Immunol Rev"},{"issue":"1","key":"2019111809113433600_B16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.immuni.2006.04.016","article-title":"Antibody repertoires generated by VH replacement and direct VH to JH joining.","volume":"25","author":"Koralov","year":"2006","journal-title":"Immunity"},{"issue":"9102","key":"2019111809113433600_B17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)10295-1","article-title":"Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia.","volume":"351","author":"Coustan-Smith","year":"1998","journal-title":"Lancet"},{"issue":"52","key":"2019111809113433600_B18","doi-asserted-by":"crossref","first-page":"21194","DOI":"10.1073\/pnas.1118357109","article-title":"High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.","volume":"108","author":"Logan","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"134","key":"2019111809113433600_B19","doi-asserted-by":"crossref","first-page":"134ra63","DOI":"10.1126\/scitranslmed.3003656","article-title":"High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia.","volume":"4","author":"Wu","year":"2012","journal-title":"Sci Transl Med"},{"issue":"7","key":"2019111809113433600_B20","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1182\/blood.V99.7.2315","article-title":"Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease.","volume":"99","author":"Szczepa\u0144ski","year":"2002","journal-title":"Blood"},{"issue":"13","key":"2019111809113433600_B21","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1182\/blood-2003-05-1455","article-title":"Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection.","volume":"102","author":"Li","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2019111809113433600_B22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/sj.leu.2401970","article-title":"Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy.","volume":"15","author":"de Haas","year":"2001","journal-title":"Leukemia"},{"issue":"2","key":"2019111809113433600_B23","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2007-01-067785","article-title":"Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone.","volume":"110","author":"Choi","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2019111809113433600_B24","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2002-10-3252","article-title":"Late relapses evolve from slow-responding subclones in t(12;21)-positive acute lymphoblastic leukemia: evidence for the persistence of a preleukemic clone.","volume":"101","author":"Konrad","year":"2003","journal-title":"Blood"},{"issue":"10","key":"2019111809113433600_B25","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.4161\/cc.7.10.5885","article-title":"Mechanism of relapse in pediatric acute lymphoblastic leukemia.","volume":"7","author":"Henderson","year":"2008","journal-title":"Cell Cycle"},{"key":"2019111809113433600_B26","article-title":"Massive evolution of the immunoglobulin heavy chain locus in children with pediatric B precursor acute lymphoblastic leukemia [published online ahead of print August 28, 2012].","author":"Gawad","journal-title":"Blood"},{"issue":"2","key":"2019111809113433600_B27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood-2011-01-333070","article-title":"High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.","volume":"118","author":"Leung","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2019111809113433600_B28","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJM199808273390904","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer\u2013Childhood Leukemia Cooperative Group.","volume":"339","author":"Cav\u00e9","year":"1998","journal-title":"N Engl J Med"},{"issue":"9142","key":"2019111809113433600_B29","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(98)04058-6","article-title":"Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.","volume":"352","author":"van Dongen","year":"1998","journal-title":"Lancet"},{"issue":"6","key":"2019111809113433600_B30","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/blood.V99.6.1952","article-title":"Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.","volume":"99","author":"Dworzak","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2019111809113433600_B31","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.","volume":"107","author":"Br\u00fcggemann","year":"2006","journal-title":"Blood"},{"issue":"3","key":"2019111809113433600_B32","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood-2006-07-037093","article-title":"Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06\/99 and 07\/03 trials.","volume":"109","author":"Raff","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111809113433600_B33","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2006-09-045369","article-title":"Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.","volume":"110","author":"Zhou","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2019111809113433600_B34","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"issue":"18","key":"2019111809113433600_B35","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood"},{"issue":"16","key":"2019111809113433600_B36","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111809113433600_B37","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","article-title":"Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.","volume":"118","author":"Schrappe","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111809113433600_B38","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.leu.2403283","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.","volume":"18","author":"Coustan-Smith","year":"2004","journal-title":"Leukemia"},{"issue":"12","key":"2019111809113433600_B39","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1038\/leu.2008.227","article-title":"Minimal residual disease is an important predictive factor of outcome in children with relapsed \u2018high-risk\u2019 acute lymphoblastic leukemia.","volume":"22","author":"Paganin","year":"2008","journal-title":"Leukemia"},{"issue":"24","key":"2019111809113433600_B40","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","article-title":"Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111809113433600_B41","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","article-title":"Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.","volume":"27","author":"Bader","year":"2009","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111809113433600_B42","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/26\/5173\/1362012\/zh805212005173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/26\/5173\/1362012\/zh805212005173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T10:17:09Z","timestamp":1574072229000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/26\/5173\/30961\/Deepsequencing-approach-for-minimal-residual"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,20]]},"references-count":42,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2012,12,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-07-444042","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,20]]}}}